Last reviewed · How we verify
Basal insulin and exenatide
This combination uses basal insulin to provide background glucose control while exenatide stimulates insulin secretion and slows gastric emptying in response to meals.
This combination uses basal insulin to provide background glucose control while exenatide stimulates insulin secretion and slows gastric emptying in response to meals. Used for Type 2 diabetes mellitus inadequately controlled on basal insulin monotherapy.
At a glance
| Generic name | Basal insulin and exenatide |
|---|---|
| Also known as | Basal insulin glargine, Exenatide |
| Sponsor | Mount Sinai Hospital, Canada |
| Drug class | Basal insulin + GLP-1 receptor agonist combination |
| Target | Insulin receptor (basal insulin); GLP-1 receptor (exenatide) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Basal insulin provides steady, long-acting glucose lowering throughout the day and night. Exenatide is a GLP-1 receptor agonist that enhances postprandial insulin secretion, slows gastric emptying, and promotes satiety, together improving glycemic control and often reducing body weight in type 2 diabetes patients.
Approved indications
- Type 2 diabetes mellitus inadequately controlled on basal insulin monotherapy
Common side effects
- Nausea
- Vomiting
- Hypoglycemia
- Diarrhea
- Headache
- Injection site reactions
Key clinical trials
- Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM (PHASE4)
- FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) (PHASE4)
- BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
- Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL) (PHASE3)
- A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) (PHASE4)
- Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes (PHASE4)
- GLP-1 REceptor Agonists and Real World EvIdeNce
- Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Basal insulin and exenatide CI brief — competitive landscape report
- Basal insulin and exenatide updates RSS · CI watch RSS
- Mount Sinai Hospital, Canada portfolio CI